Evogene (NASDAQ:EVGN) Earns Sell Rating from Analysts at StockNews.com

Equities researchers at StockNews.com began coverage on shares of Evogene (NASDAQ:EVGN) in a research report issued to clients and investors on Tuesday. The brokerage set a “sell” rating on the biotechnology company’s stock.

Separately, Alliance Global Partners reiterated a “buy” rating on shares of Evogene in a report on Friday, March 7th.

Evogene Stock Performance

Shares of NASDAQ EVGN opened at $1.43 on Tuesday. The firm has a market capitalization of $7.67 million, a P/E ratio of -0.32 and a beta of 1.28. The firm’s 50-day moving average price is $1.51 and its 200-day moving average price is $1.93. Evogene has a 1-year low of $1.20 and a 1-year high of $9.00.

Evogene (NASDAQ:EVGN) last posted its quarterly earnings results on Thursday, March 6th. The biotechnology company reported $0.06 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.72) by $0.78. Evogene had a negative return on equity of 109.05% and a negative net margin of 314.43%. The business had revenue of $1.61 million for the quarter, compared to the consensus estimate of $3.63 million. During the same period in the prior year, the business earned ($1.30) EPS.

Hedge Funds Weigh In On Evogene

An institutional investor recently bought a new position in Evogene stock. Jane Street Group LLC acquired a new position in Evogene Ltd. (NASDAQ:EVGN) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 21,345 shares of the biotechnology company’s stock, valued at approximately $40,000. Jane Street Group LLC owned about 0.40% of Evogene as of its most recent SEC filing. Hedge funds and other institutional investors own 10.40% of the company’s stock.

Evogene Company Profile

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.